key: cord-0034877-ewe2fje7
authors: Hui, David
title: Infectious Diseases
date: 2010-08-13
journal: Approach to Internal Medicine
DOI: 10.1007/978-1-4419-6505-9_8
sha: b9c7b48f635df91d2677dc62104e5617ed02d471
doc_id: 34877
cord_uid: ewe2fje7

This list is not exclusive, but highlights some important causes of FUO after the common causes of fever have been excluded:

HISTORY-pattern and duration of fever, associated symptoms (cough, dyspnea, hemoptysis, chest pain, diarrhea, abdominal pain, dysuria, urethral discharge, hematuria, neck stiffness, headache), rash (palpable purpura, exanthem), exposure (food, water, plants, animals, insects, infected human secretions), weight loss, night sweats, travel history, sexual history, HIV risk factors, immunizations, past medical history (rheumatologic disorders, malignancy, alcohol), medications PHYSICAL-vitals (tachycardia, tachypnea, hypotension, fever, hypoxemia), oral ulcers, lymphadenopathy, nuchal rigidity, respiratory and cardiac examination (murmurs), temporal artery, abdominal examination (hepatosplenomegaly), prostate examination, skin lesions (morphology, distribution), tick bite marks, joint examination

MICROBIOLOGY-blood C&S (including Mycobacteria), sputum Gram stain/AFB/C&S, urine C&S, stool C&S, O&P, serology (HBV, HCV, HIV, monospot, CMV IgM, endemic fungi) IMAGING 

AGE-viral exanthems, scarlet fever, and acute rheumatic fever are more likely in children. Mononucleosis is more common in young adults SEASON-tick-borne diseases are more common in spring and summer. Coxsackie virus and echovirus are more common in summer and fall. Meningococcus and parvovirus are more common in winter and spring GEOGRAPHIC LOCATION-Lyme disease in Pacific northwest, the Midwest, and the northeast USA and some southern Canadian locations. RMSF in south-central and Atlantic states. Ehrlichiosis in midwestern, south-central, and southeastern states. Tularemia in western, southeastern, and south-central states and Canada. Relapsing fever (Borrelia hermsii) in mountainous areas of the western USA. Endemic fungal infections include Blastomyces dermatitidis (southeastern states, Manitoba, and Ontario), Coccidioides immitis (southwestern states), and Histoplasma capsulatum (Mississippi, Ohio River valleys, and Quebec) HISTORY-pattern and duration of fever, associated symptoms (cough, dyspnea, chest pain, diarrhea, abdominal pain, dysuria, urethral discharge, neck stiffness, headache), rash (prodrome, location, progression, treatment), exposure (food, water, plants, animals, infected human secretions), weight loss, night sweats, travel history, sexual history, immunizations, past medical history (rheumatologic disorders, malignancy), medications PHYSICAL-vitals (tachycardia, tachypnea, hypotension, fever, hypoxemia), oral ulcers, lymphadenopathy, nuchal rigidity, respiratory and cardiac examination (murmurs), abdominal examination (hepatosplenomegaly), skin lesions (morphology, distribution), tick bite marks, joint examination All associated with a rash, myalgias, and headache, except Q fever and ehrlichiosis. All involve some degree of vasculitis and DIC as part of pathogenesis. All can be treated with doxycycline ROCKY MOUNTAIN SPOTTED FEVER-Rickettsia rickettsii transmitted by ticks. Most common in mid-Atlantic states. Rash begins on extremities and moves centrally. Treat with doxycycline MURINE TYPHUS-flea vector. Rash begins centrally and moves peripherally. Treat with doxycycline or chloramphenicol EHRLICHIA-E. chaffeensis (human monocytic ehrlichiosis) transmitted by lone star tick. Peaks in May to July. Infects lymphocytes, monocytes, and neutrophils intracellularly. Fever, headache, myalgia, leukopenia, thrombocytopenia, and elevated transaminases; maculopapular or petechial rash in onethird. Human granulocytic anaplasmosis is caused by a related Ehrlichia and produces similar illness without rash. Transmitted by Ixodes tick and co-infection with Lyme disease possible. Treat with doxycycline Q FEVER-Coxiella burnetii transmitted by respiratory spread from infected animal body fluids (e.g. cattle, sheep, goats, cats 19% APPROACH-''no single component of the history or physical examination emerges as one that makes the diagnosis of erythema migrans highly likely. These signs and symptoms have not been examined in combination. Laboratory testing has limited utility. In endemic areas, the combination of history of a tick bite, a solitary lesion of appropriate size, morphology and presence of systemic symptoms is consistent with erythema migrans. In non-endemic areas, these same factors are also suggestive of this diagnosis and should prompt further investigation''

JAMA 2007 48F] for >1 h, ANC <0.5Â10 9 /L or <1.0Â10 9 /L + expected nadir <0.5Â10 9 /L ABSOLUTE NEUTROPHIL COUNT (ANC)-neutrophils + bands PATHOGENESIS-chemotherapy-induced injury to mucosal barriers, immune defects due to drugs or underlying disease and invasive devices. With the attenuated immune response, patients may be relatively asymptomatic until they decompensate due to overwhelming infection. Fever is sometimes the only warning sign and should always be taken seriously in patients at risk of developing neutropenia NEUTROPENIA-ASSOCIATED FEBRILE EPISODESmost commonly idiopathic; bacterial source identified in approximately 30% of episodes, usually from patient's own endogenous flora. Fungal infections replace bacterial infections in prominence after 7 days. Fever usually abates with return of neutrophils. If fever persists or returns after neutropenia resolves, consider hepatosplenic candidiasis PATHOPHYSIOLOGY (CONT'D) HISTORY-patients usually asymptomatic other than fever. Determine severity and duration of fever, associated signs and symptoms (cough, dyspnea, chest pain, diarrhea, abdominal pain, dysuria, urethral discharge, neck stiffness, headache, rash), recent chemotherapy (nadir of neutrophil counts usually 10-14 days post-treatment), weight loss, night sweats, travel history, sexual history, immunizations, past medical history (malignancy, rheumatologic disorders), medications (chemotherapy, GCSF) PHYSICAL-vitals (tachycardia, tachypnea, hypotension, fever, hypoxemia), oral ulcers, lymphadenopathy, nuchal rigidity, respiratory and cardiac examination (murmurs), abdominal examination (hepatosplenomegaly), skin lesions (morphology, distribution). Important sites to examine include venous access devices, sinuses, and perianal region for abscess. TREATMENT ISSUES (CONT'D) primary prophylaxis was not received), in which a reduced dose may compromise disease-free survival overall survival, or treatment outcome TREATMENT OF PATIENTS WITH FEBRILE NEUTROPENIA-GCSF should be given to those with high risk of developing complications, including expected prolonged (>10 days) and profound (<0.1Â10 9 /L) neutropenia, age >65 years, uncontrolled primary disease, pneumonia, hypotension and multi-organ dysfunction (sepsis), invasive fungal infection, being hospitalized at the time of the development of fever SPECIAL SITUATIONS STEM CELL TRANSPLANT-to mobilize peripheral blood progenitor cell often in conjunction with chemotherapy. Also administered after autologous, but not allogeneic, stem cell transplantation DLBCL-prophylactic GCSF should be given for patients with diffuse aggressive lymphoma age 65 and older treated with curative chemotherapy (CHOP or more aggressive regimens) AML-may be given shortly after completion of the initial induction chemotherapy to modestly decrease the duration of neutropenia ALL-recommended after the completion of the initial first few days of chemotherapy of the initial induction or first post-remission course, thus shortening the duration of neutropenia by approximately 1 week MDS-may be used to increase the ANC in neutropenic patients. Intermittent administration of CSFs may be considered in a subset of TREATMENT ISSUES (CONT'D) patients with severe neutropenia and recurrent infections POST-RADIATION-GCSF should be given to patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs J Clin Oncol 2006 COMPLICATED UTI-presence of functional or anatomic abnormality of the urinary tract (polycystic kidney disease, nephrolithiasis, neurogenic bladder, diabetes, immunosuppression, pregnancy, indwelling urinary catheter, recent urinary tract instrumentation) UNCOMPLICATED UTI-absence of risk factors above. In women, uncomplicated UTIs are usually treated for 3 days (or 5-7 days with nitrofurantoin) PYELONEPHRITIS-usually 18-40-year-old women, fever, costovertebral angle tenderness, blood and urine cultures indicated. Challenges differentiating between cystitis and pyelonephritis RISK FACTORS FOR UTI YOUNG WOMEN-frequent or recent sexual activity ELDERLY WOMEN-age, estrogen deficiency, incontinence, diabetes, cystoceles, previous GU surgery PATHOPHYSIOLOGY OF CATHETER-ASSOCIATED BACTERIURIA-bacteria establish biofilm in or on catheter and enter bladder intra-or extraluminally. PLAIN FILMS-soft tissue swelling and gas, cortical destruction, periosteal new bone formation, foreign bodies, deformities, fractures, and soft tissue gas. Usually the first imaging to investigate for osteomyelitis. However, may not detect changes until after 2-3 weeks of infection. May help make diagnosis of osteomyelitis but never excludes it (sens 61%, spc 72%, PPV 80% for diabetic foot osteomyelitis) BONE SCAN-more sensitive but less specific than plain films (sens 70-100%, spc 36% for diabetic foot osteomyelitis). Useful for ruling out osteomyelitis, but cannot make the diagnosis INDIUM-LABELED LEUKOCYTE SCAN-better sensitivity and specificity (but still poor) than bone scans in diabetic foot. Since WBC accumulates in the marrow, the scan is less sensitive in areas with red marrow (vertebrae, pelvis). Excellent for fracture nonunion osteomyelitis (sens 91%, spc 97%) MRI-provides great anatomic details, more sensitive and specific than bone scan. Imaging of choice for specific body sites (vertebrae, diabetic foot) (sens 72%)

ULTRASOUND-fluid collection adjacent to the bone without intervening soft tissue, elevation of the periosteum by >2 mm, and thickening of the periosteum. Sensitivity and specificity uncertain BONE BIOPSY-gold standard for osteomyelitis and generally required in vertebral osteomyelitis. Positive blood cultures and corresponding radiologic findings may support diagnosis and sometimes replace bone biopsy. Consider holding off antibiotic therapy if not life-threatening infection to facilitate identification of organisms. Organisms from skin swabs have little correlation with the actual organisms growing inside the bone, except for S. aureus

Diabetes Mellitus (p. 337) MANAGEMENT HEMATOGENOUS-for vertebral osteomyelitis, need blood and bone cultures, then start empiric antibiotics with cloxacillin 2 g IV q4-6h or cefazolin 2 g IV q8h. Consider vancomycin 15 mg/kg IV q12h if high local MRSA rates. Once organism identified, treat with specific antibiotic (total 6-12 weeks of antibiotics guided by susceptibility from time of biopsy or definitive surgery, with at least 2 weeks of IV therapy). If failed therapy, consider bone/soft tissue debridement and another 4-6 weeks of antibiotics after definitive surgery CONTIGUOUS SPREAD WITHOUT VASCULAR INSUFFICIENCY-after orthopedic surgery and specimen collection, start vancomycin 15 mg/kg IV q12h AE ceftazidime 2 g IV q8h. For sternal osteomyelitis, give vancomycin 15 mg/kg IV q12h, then switch to specific antibiotics (total 6 weeks of antibiotics from time of definitive surgery, usually intravenous for the duration) CONTIGUOUS SPREAD WITH VASCULAR INSUFFI-CIENCY-polymicrobial. Base therapy on bone culture, empirical coverage should include anaerobes (e.g. carbapenems, piperacillin-tazobactam) (within 3 months of surgery), short duration of symptoms (<3 weeks) with no sinus tract, a stable implant and a causative organism susceptible to quinolones (or trimethoprim-sulfamethoxazole) and rifampin, which are given for 3 months (hips) to 6 months (knees) after an initial course of appropriate IV antibiotic therapy for at least 2 weeks. If debridement and retention are not appropriate, removal of the infected prosthesis with one-stage or two-stage exchange; IV antibiotic therapy is also provided for 6 weeks following the initial surgery NEJM 2009 inhibitors, alcohol abuse, malnutrition, liver or kidney disease, poorly controlled diabetes, smoking, gastrectomy, jejunoileal bypass

PRIMARY TB SYMPTOMS-fever, night sweats, pleuritic chest pain, chronic cough, anorexia, weight loss, fatigue, erythema nodosum SIGNS-often none. Primary TB usually involves the mediastinal lymph nodes; hilar lymphadenopathy in the presence of RML collapse is the most common radiologic finding (2/3) with pleural effusion in 1/3. Lung infiltrates may be seen and involve lower lungs or middle lung fields most commonly with possible cavitation in areas of consolidation REACTIVATION TB (active pulmonary) SYMPTOMS-cough, yellow-green sputum (increases over time), hemoptysis (25%), chest pain/dyspnea (33%), fever/night sweats (50%), fatigue (50-66%), weight loss SIGNS-reactivation TB usually involves the apicalposterior segments of upper lobes (80-90%), cavitation (19-40%), hilar lymphadenopathy (more likely than cavitation in AIDS patients) ELDERLY WITH REACTIVATION TB-presents with fever, night sweats, or hemoptysis less often. Lesions less often cavitary and less often TST positive COMPLICATIONS OF PULMONARY TB-hemoptysis (rarely massive), pneumothorax (more common in endemic countries), bronchiectasis, and pulmonary destruction (rare) AFB-negative sputum samples support that patient is non-infectious and can come off isolation LIMITATIONS-smear only detects 50% of culturepositive TB, and in non-endemic areas positive smear may represent non-TB mycobacterium STAINING AGENTS-standard is Ziehl-Neelsen (acid fast stain); Auramine-Rhodamine or Auramine O fluorescence staining improves sensitivity but must be confirmed with acid fast SPUTUM CULTURE-2-8 weeks in egg media, 4-14 days if radiometric (sens 80-85%, spc 98-99%) POLYMERASE CHAIN REACTION (PCR)-more useful in non-endemic countries to rule out other common mycobacteria. High specificity but variable sensitivity (if AFB positive, sens 94-96%, spc 99.7-100%. If AFB positive, sens 9-100%, spc 25-100%) INTERFERON GAMMA RELEASE ASSAYS-sensitivity >95%; not affected by prior BCG vaccination. Most useful for evaluation of latent TB in those with positive TST and previously vaccinated with BCG MANAGEMENT LATENT TB INFECTION-isoniazid 300 mg PO daily Â6-12 months or rifampin 600 mg PO daily Â4 months. A "decision to tuberculin test is a decision to treat'' with no age cutoff for treatment and regardless of BCG vaccination status. Exclude active TB with sputum culture and CXR before treatment. HIV, immunosuppressed, and newly infected patients should be priority for treatment of latent TB PRIMARY OR REACTIVATION TB-patients should be isolated in single rooms with negative air pressure. TB therapy should be undertaken in consultation with an expert. Susceptibility testing is necessary to guide treatment. Directly observed treatment (DOT) is the standard of care for all patients. TB therapy consists of an intensive phase of daily therapy followed by a continuation phase of twice-or thrice-weekly therapy. wRIPEw Rifampin 10 mg/kg or 600 mg PO daily, isoniazid 5 mg/kg or 300 mg PO daily, pyrazinamide 20-25 mg/kg PO daily Â8 weeks. Ethambutol 15-20 mg/kg PO daily is added until drug susceptibility results are available. This is followed by isoniazid and rifampin daily, twice weekly, or three times weekly for 16 more weeks. Alternatives include isoniazid, rifampin, pyrazinamide, plus ethambutol or streptomycin three times weekly for 24 weeks, or isoniazid, rifampin, pyrazinamide, plus ethambutol for 2 weeks, then twice weekly for 6 weeks, followed by isoniazid and rifampin twice weekly for 16 weeks (see guidelines for exceptions and alternate regimens when faced with resistance or drug intolerance) S. AUREUS (MSSA)-may develop resistance to penicillin by b-lactamase PSEUDOMONAS-various intrinsic mechanisms conferring resistance. Need to treat with dual antibiotic therapy for serious infections if therapy for >2 weeks or if susceptibility not yet available VRE-vancomycin-resistant enterococci MRSA-S. aureus that is resistant not only to penicillin, but also penicillinase-resistant penicillins (methicillin, nafcillin, oxacillin). In general, hospital MRSA strains have broader resistance (e.g. clindamycin, trimethoprim-sulfamethoxazole, tetracyclines) than community-associated MRSA strains (CA-MRSA). Risk factors for hospital MRSA infections include frequent hospital visits and contact with MRSA-infected individuals; CA-MRSA is associated with crowding, acute and chronic skin disease, poor hygiene, sharing of contaminated items, contact sports, and IDU b-LACTAMASE-RESISTANT BACTERIA-constitutive (E. coli*, Klebsiella*, Haemophilus, Neisseria, bacteroides), inducible (S. aureus, Serratiay*, Providenciay, Pseudomonas, Indole-positive Proteusy*, Citrobactery*, Enterobactery*, Morganellay*) ywSPICE-Mw organisms with inducible, chromosomally mediated cephalosporinases (AmpC type b-lactamases) resistant to penicillins, first and second generation cephalosporins, cephamycins, and b-lactamase inhibitors *these organisms may have extended spectrum b-lactamase (ESBL) resistant to all b-lactams except carbapenems <25 mL/min, single dose then measure serum concentration and give PRN). Changes in dose without changes in interval will result in proportional changes in both peak and trough serum drug concentrations. Prolongation of dosing interval will also reduce both, particularly trough level HISTORY-characterize reaction (age when reaction occurred, timing of reaction after penicillin administration, type of reaction, route of administration, reason for penicillin, any other medications at the time, resolution), any similar antibiotics since CROSS-REACTIVITY-incidence of cross-reactivity to cephalosporins when patient has penicillin allergy by history is <2%. Carbapenems and first/secondgeneration cephalosporins have higher cross-reactivity in the penicillin allergic than third-generation cephalosporins and aztreonam. It is often safe to use these medications, with the first dose monitored. DIFFERENTIAL DIAGNOSIS BRAIN ABSCESS-toxoplasma (CD4 <100/mm 3 , usually multiple ring-enhancing lesions), tuberculosis (any CD4), Cryptococcus (CD4 <100/mm 3 ), Histoplasma (CD4 <500/mm 3 ), aspergillosis CNS LYMPHOMA (CD4 <100/mm 3 ) PROGRESSIVE MULT-IFOCAL LEUKOENCEPHALOPATHY (PML, CD4 <100/mm 3 )-reactivation of JC virus, hypodense white matter lesion DIAGNOSIS-CBCD, lytes, urea, Cr, blood C&S, toxoplasma IgG antibodies, EBV PCR, JC virus PCR, CT/MR head, PET scan (CNS lymphoma has higher activity than abscess), brain biopsy (if suspect CNS lymphoma). The combination of (1) multiple ring enhancing lesions, (2) positive antitoxoplasmosis antibodies, and (3) lack of toxoplasma prophylaxis in a HIV patient with CD4 count <100/mm 3 has 90% PPV for diagnosing toxoplasma TREATMENT OF TOXOPLASMOSIS-pyrimethamine plus either sulfadiazine or clindamycin DIFFERENTIAL DIAGNOSIS CRYPTOCOCCUS (CD4 <100/mm 3 )-ubiquitous fungus. High opening pressure (>200 cmH 2 O) BACTERIAL MENINGITIS (any CD4)-N. meningitis, S. pneumoniae, Listeria, Gram-negative bacilli VIRAL MENINGITIS (any CD4)-HSV encephalitis DIAGNOSIS-CBCD, lytes, urea, Cr, blood C&S, serum CRAG (sens 95% for Cryptococcus), CT head, lumbar puncture (for Cryptococcus and cryptoantigen) TREATMENT OF CRYPTOCOCCUS-induction with amphotericin B 0.7 mg/kg IV daily plus flucytosine 25 mg/kg PO QID, switch to fluconazole 400 mg PO daily Â2 months for consolidation, followed by fluconazole 200 mg PO daily as maintenance. Management of increased intracranial pressure may be needed

COMMUNITY-ACQUIRED PNEUMONIA (any CD4)-most common cause is S. pneumoniae. Others include Moraxella, H. influenzae TUBERCULOSIS (any CD4)-170Â increased risk in HIV patients. May be extrapulmonary NON-TB MYCOBACTERIUM-MAC (CD4 <100/mm 3 , pulmonary involvement alone is rare, usually disseminated) FUNGAL (CD4 <500/mm 3 )-Histoplasma, Coccidioides, Cryptococcus PNEUMOCYSTIS JIROVECII PNEUMONIA (PJP, CD4 <200/ mm 3 ) DIAGNOSIS-CBCD, lytes, urea, Cr, LDH (" in PJP but non-specific), blood C&S and mycobacterial culture, sputum C&S and AFB, ABG, urine C&S, CXR, bronchoscopy (lavage, biopsy) TREATMENT OF PJP-trimethoprim-sulfamethoxazole 15 mg of TMP/kg PO/IV divided q8h daily Â21 days. If severe disease (PaO 2 <70 mmHg), add prednisone 40 mg PO BID Â5 days, then 40 mg PO daily Â5 days, then 20 mg PO daily Â11 days. Alternatives to trimethoprim-sulfamethoxazole include dapsone plus trimethoprim, or clindamycin plus primaquine, pentamidine IV. Use atovaquone if G6PD deficiency 

KAPOSI'S SARCOMA (any CD4)-strongly associated with HHV8. Lesions may involve skin, oral mucosa, lungs, and GI tract. Treat with liposomal doxorubicin NON-HODGKIN'S LYMPHOMA (CD4 <100/mm 3 )-diffuse large B-cell lymphoma, primary effusion lymphoma (associated with HHV8 and EBV), and plasmablastic lymphomas. Treat with combination chemotherapy (CHOPR) PRIMARY CNS LYMPHOMA (CD4 <100/mm 3 )-strongly associated withEBV.Treat with radiation and/or highdose methotrexate or intrathecal chemotherapy CERVICAL CARCINOMA (any CD4)-strongly associated with HPV. Treat with surgery, radiation, and/or chemotherapy (cisplatin) MICROBIOLOGY-formerly believed to be unicellular yeast, although now confirmed to be dimorphic. Unlike other dimorphic fungi (e.g. Histoplasma, Blastomyces, and Coccidioides), Cryptococcus is ubiquitous and not geographically isolated. Cryptococcus neoformans has two varieties: C. neoformans var. neoformans and var. gattii PATHOPHYSIOLOGY C. NEOFORMANS-almost invariably in immunocompromised patients including HIV with CD4 <100/ mm 3 , transplantation, hematologic malignancies, chronic kidney diseases, diabetes mellitus, cirrhosis, or corticosteroid use. This pathogen is inhaled, then disseminates with predilection for CNS with meningitis more common than focal parenchymal infections C. GATTII-seen more commonly in immunocompetent hosts and paradoxically uncommon in immunosuppressed hosts. Symptomatic infection is usually pulmonary AE focal parenchymal brain infection CLINICAL FEATURES-CNS, pulmonary, and cutaneous involvement (but may involve any organ) TREATMENTS-CNS infection (lumbar puncture to lower intracranial pressure, amphotericin B plus flucytosine, followed by fluconazole), pulmonary or cutaneous infection (fluconazole or itraconazole) CID 2010 50:3 COCCIDIOIDOMYCOSIS PATHOPHYSIOLOGY-endemic to lower deserts of southern Arizona, central California, southwestern New Mexico, and west Texas in USA. Also Mexico, Central and South America. Peak incidence from May-July and October-December. Affects mostly patients with immunosuppression CLINICAL FEATURES-an acute pulmonary infection that is often asymptomatic, but can cause a flu-like illness or pneumonia. Pulmonary symptoms include chest pain, cough, fever, and hemoptysis if cavitary lesions. Radiologically, unilateral infiltrate and hilar adenopathy are common. Cutaneous symptoms include erythema nodosum and erythema multiforme. Most common sites of dissemination are skin, bone, and meninges DIAGNOSIS-fungal culture and serology. Note that Cocciodioides is a level 3 pathogen. Therefore, cultures should be processed in high-level isolation unit and labeled carefully. DEFINITION-infections acquired in hospital that occur between 72 h after admission and 72 h after discharge (up to 30 days for surgical procedures) URINARY TRACT INFECTIONS-secondary to urinary catheters. Infection rates are 1-5%, up to 100% for long-term catheterization. Complications include cystitis, prostatitis, pyelonephritis, and urosepsis VENTILATOR-ASSOCIATED PNEUMONIAS-secondary to endotracheal tube insertion (>48h, p. 94) BACTEREMIA-secondary to central venous catheters. Infection rates are 3-7% SURGICAL SITE INFECTIONS-secondary to incisions PREVENTION STRATEGIES-hand washing, hand washing, and hand washing. Education, isolation, and surveillance are important. Practice routine/standard/universal precautions with the use of gloves when handling all body fluids except sweat. Always use sterile technique when inserting urinary and central venous catheters. Minimize NG tube insertion and keep patient erect if intubated ISOLATION AIRBORNE (negative pressure room with high-efficiency particulate aerator filter, certified N95 respirator for personal protection)-varicella, tuberculosis. Negative pressure room required DROPLET (mask within 3-6 feet; eye protection)-H. influenzae, N. meningitidis, influenza, RSV, pertussis CONTACT (glove, gown, wash hands)-C. difficile, VRE, MRSA N. MENINGITIDIS PROPHYLAXIS CHEMOPROPHYLAXIS-for exposures in last 7 days with ciprofloxacin 500 mg PO Â1 dose or rifampin 600 mg PO BID Â2 days can be used to reduce the risk of N. meningitidis in ''close contacts.'' Vaccines are not recommended for primary prophylaxis post-exposure, but may be useful for epidemic control on a population basis

CLOSE CONTACTS-defined as healthcare workers with direct exposure to respiratory secretions (e.g. mouth-to-mouth resuscitation or intubation), household members, intimate contacts, children in school environments, coworkers in the same office, young adults in dormitories, and recruits in training centers. Not recommended for most medical personnel (i.e. those without direct exposure to patient's oral secretions) or for casual or indirect contacts (e.g. school or workmates)

PREVENTION-routine/standard/universal precautions (gloves, gowns, masks if risk of exposure of body fluids), never recap needles, education PRE-EXPOSURE PROPHYLAXIS-immunization (hepatitis B vaccine at 0, 1, 6 months, influenza) RISK OF TRANSMISSION-depends on the mechanism of exposure, source patient characteristics, preand post-exposure prophylaxis HBV-6-30% if source positive. Transmission via urine, feces, and saliva unlikely HCV-1.8% if source positive. Transmission via urine and feces unlikely HIV-0.3% if source positive. Transmission via urine, feces, and saliva unlikely POST-EXPOSURE PROCEDURE SOURCE PATIENT TESTING-HBV, HCV, HIV EXPOSED PERSON BASELINE TESTING-HBV, HCV, HIV (ELISA, Western), CBCD, lytes, urea, Cr, AST, ALT, ALP, bili HBV PROPHYLAXIS-HB Ig (only if source patient is HBsAg positive or unknown and the exposed person is unvaccinated) and start vaccination for HBV HIV PROPHYLAXIS-antiretroviral (if source patient HIV positive). Therapy may include zidovudine and lamivudine AE protease inhibitor such as lopinavir/ 

RISK FACTORS FOR SPECIFIC ORGANISMS HBV-household contacts/sexual partners of hepatitis patients, IDU, homosexual, multiple sexual partners, tattoo, piercing, transfusions, healthcare workers (prior to vaccine era), residents/workers of institutions for mentally ill or criminals, birth in endemic country HCV-sexual partners (controversial), IDU, tattoo, piercing, transfusions, residents/workers of institutions for mentally ill or criminals PNEUMOCOCCAL

INFLUENZAE-splenectomy CONTRAINDICATIONS ALL VACCINES-anaphylaxis, severe illness LIVE VACCINES-pregnancy, immunocompromised (steroids, AIDS but not HIV, malignancies) SIDE EFFECTS-local erythema

NUCLEOSIDE AND NUCLEOTIDE REVERSE TRAN-SCRIPTASE INHIBITORS (NRTI)-zidovudine (ZDV, AZT), stavudine (d4T), didanosine (ddI), lamivudine (3TC), abacavir (ABC), tenofovir (TDF), and emtricitabine (FTC). Major side effects include hepatic steatosis, lactic acidosis, neuropathy, anemia, pancreatitis, and renal disease NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI)-efavirenz (EFV), nevirapine (NVP), etravirine (ETR). Major side effects include rash, Stevens-Johnson syndrome, hepatitis, and CNS complications PROTEASE INHIBITORS (PI)-saquinavir (SQV), indinavir (IDV), nelfinavir (NFV), lopinavir-ritonavir (LPV/ RTV), fosamprenavir (FPV), atazanavir (ATV), tipranavir (TPV), and darunavir (DRV